Effectiveness and Safety of Antidiabetic Medications in Hidradenitis Suppurativa: A Systematic Review
Abstract
Purpose: Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition often linked with metabolic dysfunction and insulin resistance. Antidiabetic medications have been explored as adjunctive therapies due to their anti-inflammatory and anti-androgenic effects. This systematic review evaluated the effectiveness and safety of antidiabetic agents in HS management.
Patients and methods: A comprehensive search was conducted in PubMed, Scopus, Web of Science, CINAHL Ultimate, and Google Scholar. Eligible studies assessed the efficacy or safety of antidiabetic drugs in HS patients. Fifteen studies, comprising 3721 participants, met inclusion criteria.
Results: Metformin was the most studied drug, included in 10 studies. Several investigations showed reductions in HS lesion counts, flare frequency, and disease severity scores (Hurley stage, Sartorius score, Visual Analog Scale). Quality of life improvements, measured by the Dermatology Life Quality Index (DLQI), were observed with metformin, liraglutide, and tirzepatide. Gastrointestinal side effects were the most frequently reported, particularly with metformin. However, no severe or unexpected adverse events were linked to GLP-1 receptor agonists or SGLT2 inhibitors.
Conclusion: Overall, antidiabetic medications, especially metformin and GLP-1 receptor agonists, appear beneficial for HS. They may reduce disease severity and improve quality of life while maintaining a favorable safety profile. Nevertheless, additional…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 3,721 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.